Navigation Links
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
Date:12/11/2008

NEW YORK, Dec. 11 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP") System for the treatment of cancers of the liver, announced today that the first fifty percent (46 of 92) of patients have been enrolled in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver. The eleven participating cancer centers in this trial continue to evaluate and enroll patients and the Company looks forward to completing enrollment in 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

Commenting on this important event, Richard L. Taney, President and Chief Executive Officer of Delcath, stated, "Enrollment of the forty-sixth patient in this trial represents a significant milestone for our Company as we continue to accelerate this trial and accrue the data to support FDA approval of the Delcath PHP System. Attaining the midpoint of this trial, on the heels of expanding to eleven centers, is an important confirmation that the Company remains on the clinical and regulatory schedule discussed with investors over the past six months. The clinical data for the first 46 patients will be submitted to the Data Safety Monitoring Board for evaluation, once we complete the collection of follow-up data on the recently treated patients. We look forward to updating our investors during our upcoming conference call to be held next month."

This multi-center clinical study is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under this CRADA, patients for this study are being treated at the NCI and at ten cancer centers
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. QMed, Inc. Reports July Medicare SNP Enrollments
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
4. Human Genome Sciences Completes Enrollment Ahead of Schedule in Second Phase 3 Albuferon(R) Trial
5. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
8. Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
9. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
11. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , Apr. 21, 2015 Research and Markets ... addition of the "Complete 2015-16 Induced Pluripotent ... their offering. Stem cell research and ... five decades, as stem cells have the unique ... their unspecialized nature allows them to differentiate into ...
(Date:4/21/2015)... 21, 2015 AbilTo, Inc., the nation,s leading ... submission has been accepted as a presentation to be ... taking place on June 5-6, 2015 in Boston, ... American Diabetes Association, the cost of diabetes to the ... a result of increased inpatient, outpatient, and pharmacy costs, ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... Dr. Mark W. Sawicki , Chief ... Annual BioLogistics Summit in San Francisco, ...
(Date:4/21/2015)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced today ... results before market open on Tuesday, April 28, 2015. ... on Tuesday, April 28, 2015, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
Breaking Biology Technology:Global Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... AGREEMENT PROVIDES CORGENIX EXCLUSIVE WORLDWIDE RIGHTS TO ... FOR CARDIOVASCULAR INFLAMMATION, DENVER, March 18 ... a worldwide developer and marketer of,diagnostic test ... the Okayama,Prefecture Industrial Promotion Foundation covering new ...
... 18 Visionsense Corp. announces,FDA 510(k) Clearance ... Vision,System. The system is based on a ... targeting Minimal Invasive,laparoscopic and endoscopic Surgery (MIS)., ... enhances MIS surgical,procedures that are under served ...
... 18 /PRNewswire/ - Aegera Therapeutics announced today,the ... trial for AEG33773, a,novel, orally bioavailable small ... diabetic neuropathy. The Phase I study will ... AEG33773 using a randomized,double blind, placebo controlled, ...
Cached Biology Technology:Corgenix Signs Technology Licensing Agreement With Japanese Government 2Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... virus (HCV) are at an increased risk of developing ... a study published in the May 8, 2007, issue ... Researchers from the National Cancer Institute (NCI), part of ... Medicine, found that HCV infection increased the risk of ...
... certain neurodegenerative diseases, such as mad cow disease or ... of infectious protein called a prion. Remarkably, in recent ... beneficial roles in biology, and prions even may act ... , But although prions have received a great deal ...
... central Catalonia, is so delicate that experts cannot get physically ... the years since the tracks were discovered they have been ... weathered and eroding at a rapid rate. , To ... near-vertical rock faces. , Palaeontologists feared the tracks could ...
Cached Biology News:Risk of lymphoma increases with hepatitis C virus infection 2Scientists identify prion's infectious secret 2Scientists identify prion's infectious secret 3Diminishing dinosaur steps saved by laser and laptop 2Diminishing dinosaur steps saved by laser and laptop 3
Human SOST Affinity Purified Polyclonal Ab...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Human FADD Affinity Purified Polyclonal Ab...
... triple quadrupole 1200L sets the new ... environment - incorporating the latest technologies ... liquid chromatography analytical needs. The ... the Transmission Quadrupole Analyzer provide superior ...
Biology Products: